DaVita Rx: Paid Claims for Medicine Left Sitting

In the DaVita Rx false claims settlement, the pharmacy agreed to pay $63.7 million over allegations of billing for undelivered or returned drugs, missing delivery and refill documentation, and financial inducements to patients. The complaint describes medication that never shipped and medicine left sitting uncollected while the government paid. For someone handling pharmacy claims, shipping or patient accounts, the question is familiar: what happened to the prescription after the payment went through?

DaVita Rx LLC was a nationwide pharmacy specializing in patients with severe kidney disease, based in Coppell, Texas. The Department of Justice announced the settlement on December 14, 2017. This pharmaceutical fraud case brought together the pharmacy’s self-disclosures and a later qui tam case brought by two people who worked for the pharmacy.

What DaVita Rx Allegedly Billed

The government alleged that DaVita Rx billed federal healthcare programs for prescriptions that never shipped, prescriptions shipped and later returned, and prescriptions without the required proof of delivery, refill requests or patient consent. The amended complaint describes how a transaction inside the pharmacy could become a government payment without a drug leaving the building:

What should have been a test allegedly brought in real money for a shipment that never happened. Taxpayers paid, but no medicine left the pharmacy. A paid claim could therefore look complete in the billing system while the shipping record had nothing to match it.

The complaint described a different failure after shipping: uncollected medicine. The whistleblowers alleged that DaVita Rx left the medicine sitting there instead of reversing the shipment and reimbursing the government. The package had moved, but the patient had not received the medication the government was paying for.

Why Payment and Delivery Tell Different Stories

A pharmacy’s payment authorization and a patient’s receipt of medicine are separate events. The drug’s physical journey and the flow of money run through different systems and participants. DaVita Rx’s alleged billing failures sit at the point where those accounts should meet.

The 2020 University of Portsmouth doctoral thesis Exploring U.S. Pharmacists’ Willingness to Fill Prescriptions Illegally explains the electronic transaction: the pharmacy sends patient and drug information, and a pharmacy benefit manager’s software checks eligibility, sets the price and determines the patient’s copay. The thesis uses a hypothetical claim without a prescription to show how payment can travel through the system even when no medicine is dispensed. An approval response and a delivery record answer different questions.

The whistleblowers also alleged that medication picked up at dialysis centers was coded as though patients had collected it at a pharmacy. They alleged that prescriptions shipped directly to dialysis centers belonged in Medicare Part B dialysis billing, but DaVita Rx sought a separate prescription payment under Part D.

For an insider, the useful connection is between the pickup location entered on the claim and the place that actually received the medicine. In the complaint’s account, the location code and the choice of Medicare payment program were part of the alleged mismatch. A shipment record could explain a billing problem that the claim alone concealed.

How Do Pharmaceutical Kickbacks Work?

Pharmaceutical kickbacks use financial benefits to influence purchases paid for by federal health care programs. In DaVita Rx’s case, the alleged benefits went to patients. The government alleged that the pharmacy accepted manufacturer copayment discount cards instead of collecting Medicare copayments, routinely wrote off unpaid beneficiary debt, and gave discounts to beneficiaries who paid for medication by credit card.

Each practice affected the patient’s side of the bill. The card substituted for copay collection. The write-off removed an unpaid patient balance. The credit-card discount reduced the amount a patient paid.

The Department of Health and Human Services’ Office of Inspector General explains why manufacturer copay coupons affect more than the patient’s bill. A coupon reduces or eliminates the patient’s immediate expense for a particular prescription. Removing the copayment can weaken price competition and encourage selection of an expensive brand drug when a less expensive, equally effective alternative is available.

The patient sees a smaller bill. The government can still face the cost of the prescription. In the DaVita Rx allegations, that makes the patient-account decision part of the same story as the claim submitted for payment.

What Are Red Flags for Pharmacists?

The DaVita Rx allegations point to paid claims without matching shipments, uncollected medicine without a reversal or refund, and missing delivery, refill-request or consent records. The complaint also identified pickup coding that allegedly described a different location from the one patients used.

For someone in billing or patient accounts, the corresponding question concerns the copay: what did the claim say the patient owed, and what did the pharmacy collect, discount or write off? Those records connect the alleged financial benefit to the same prescription that generated the government payment.

We examine those connections with the insider who understands the work. A shipping employee may recognize the gap between dispatch and pickup. A billing employee may understand why a claim remained paid. A patient-account employee may know how discounts and write-offs were authorized. Their knowledge gives the transaction records their meaning.

What the DaVita Rx Settlement Covered

The settlement total included approximately $22.2 million that DaVita Rx had already repaid to federal healthcare programs following its self-disclosure. The agreement called for an additional $38.3 million payment to the United States and allocated $3.2 million for Medicaid claims by states choosing to participate.

How Much Money Do Pharmaceutical Whistleblowers Get for Exposing Fraud?

The two former employees who brought the DaVita Rx case were allocated roughly $2.1 million from the federal recovery as their whistleblower reward.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

A Refill Request Is Part of the Transaction

In a separate Walmart and Sam’s Club settlement announced in May 2018, the government alleged that automatic refills violated Minnesota Medicaid’s requirement for a beneficiary request for each refill. DaVita Rx’s settlement likewise included allegations about missing refill-request documentation. The patient’s request can be part of what supports the pharmacy’s claim for payment, with a record of its own.

You Know What Happened After the Claim

If you know why a pharmacy kept a payment for medicine a patient never received, or how patient discounts supported federally paid prescriptions, talk with our whistleblower experts. We build the case with you around those decisions, bring in pharmaceutical fraud whistleblower lawyers who understand pharmacy billing, and stay beside you through the pursuit of a recovery.